You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Metastatic Disease Considerations in Triple Negative Breast Cancer

  • Authors: Carey K. Anders, MD; Priscilla Brastianos, MD; Lidia Schapira, MD, FASCO; Neelima Vidula, MD; Rita Nanda, MD; Sara A. Hurvitz, MD
  • CME / ABIM MOC / CE Released: 12/8/2022
  • Valid for credit through: 12/8/2023
Start Activity

  • Credits Available

    Physicians - maximum of 2.00 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 2.00 ABIM MOC points

    Nurses - 2.00 ANCC Contact Hour(s) (1.5 contact hours are in the area of pharmacology)

    Pharmacists - 2.00 Knowledge-based ACPE (0.200 CEUs)

    IPCE - 2.0 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for hematologists/oncologists, pathologists, surgeons, nurse practitioners (NPs), physician assistants (PAs), pharmacists, and nurses.

The goal of this activity is for learners to be better able to understand the spectrum of breast cancer treatment and provide strategies that can help translate data updates to improvements in patient care.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical trials investigating emerging small molecules in mTNBC
    • Emerging data related to novel therapies for the management of patients with mTNBC
    • Concerns associated with brain metastases in TNBC
  • Have greater competence related to
    • Incorporating guideline-based decision making into the development of treatment plans for patients with mTNBC
    • Incorporating shared decision into the development of treatment plans for patients with breast cancer
  • Demonstrate greater confidence in their ability to
    • Incorporate interprofessional strategies into breast cancer care


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Carey K. Anders, MD

    Professor of Medicine, Division of Medical Oncology
    Division Chief of Medical Oncology, Interim
    Medical Director, Duke Center for Brain and Spine Metastasis
    Translating Duke Health Scholar
    Duke Cancer Institute
    Duke University Health System
    Durham, North Carolina

    Disclosures

    Carey K. Anders, MD, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca; Athenex (former); Eisai; Elucida (former); Genentech; Immunomedics (former); IPSEN; Novartis (former); Seagen, Inc. (former)
    Research funding from: G1 Therapeutics; Lilly; Merck; Nektar; Novartis; Pfizer; PUMA; Seagen, Inc.; Tesaro; ZION

  • Priscilla Brastianos, MD

    Associate Professor of Medicine
    Director, Central Nervous System Metastatic Center
    Massachusetts General Hospital
    Harvard Medical School
    Boston, Massachusetts

    Disclosures

    Priscilla Brastianos, MD, has the following relevant financial relationships:
    Consultant or advisor for: Advise Connect Inspire; Dantari; ElevateBio; Pfizer; Sintetica; SK Life Science; Voyager Therapeutics
    Speaker or member of speakers bureau for: Pfizer
    Research funding from: Bristol Myers Squibb; Lilly; Merck; Mirati

  • Lidia Schapira, MD, FASCO

    Professor of Medicine (Oncology)
    Stanford University School of Medicine
    Director Cancer Survivorship Program
    Associate Director, Office of Cancer Health
    Equity and Community Engagement
    Stanford Cancer Institute
    Stanford, California

    Disclosures

    Lidia Schapira, MD, FASCO, has the following relevant financial relationships:
    Consultant or advisor for: Blue Note Therapeutics; Novartis

  • Neelima Vidula, MD

    Assistant Professor of Medicine
    Harvard Medical School
    Breast Medical Oncologist
    Massachusetts General Hospital
    Boston, Massachusetts

    Disclosures

    Neelima Vidula, MD, has the following relevant financial relationships:
    Consultant or advisor for: Aadi (former); Gilead (former); Oncosec (former)
    Research funding from: Daehwa; Merck; Novartis; Pfizer; Radius

  • Rita Nanda, MD

    Associate Professor of Medicine
    Director, Breast Oncology Program
    The University of Chicago
    Chicago, Illinois

    Disclosures

    Rita Nanda, MD, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca; BeyondSpring; Cardinal Health; Fujifilm; Gilead; Immunomedics; Infinity; iTeos; MacroGenics; Merck; OBI Pharma; OncoSec; Seagen, Inc.
    Research funding from: Arvinas; AstraZeneca; Celgene; Corcept Therapeutics; Genentech; Immunomedics; Merck; OBI Pharma; Odonate Therapeutics; OncoSec; Pfizer; Roche; Seagen, Inc.; Taiho

  • Sara A. Hurvitz, MD

    Professor
    Director, Breast Cancer Clinical Trials Program
    David Geffen School of Medicine
    University of California Los Angeles
    Medical Director
    Jonsson Comprehensive Cancer Center
    Clinical Research Unit
    Los Angeles, California

    Disclosures

    Sara A. Hurvitz, MD, has the following relevant financial relationships:
    Contracted researcher for: Ambrx; Amgen; Arvinas; AstraZeneca; Bayer; Cytomx; Daiichi Sankyo; Dignitana; Genentech; Gilead; GlaxoSmithKline; Immunomedica; Lilly; Macrogenics; Novartis; Pfizer; OBI Pharma; Orinove; Phoenix Molecular Designs, Ltd.; Pieris; PUMA; Radius; Roche; Sanofi; Seagen, Inc.; Zymeworks

Editor

  • John Churchwell, MS, PhD

    Medical Education Director, Medscape, LLC

    Disclosures

    John Churchwell, MS, PhD, has the following relevant financial relationships:
    Formerly employed by an ineligible company: Medtronic

Compliance Reviewer/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 2.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 2.0 contact hour(s) of continuing nursing education for RNs and APNs; 1.50 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape, LLC designates this continuing education activity for 2.0 contact hour(s) (0.200 CEUs) (Universal Activity Number JA0007105-0000-22-394-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Metastatic Disease Considerations in Triple Negative Breast Cancer

Authors: Carey K. Anders, MD; Priscilla Brastianos, MD; Lidia Schapira, MD, FASCO; Neelima Vidula, MD; Rita Nanda, MD; Sara A. Hurvitz, MDFaculty and Disclosures

CME / ABIM MOC / CE Released: 12/8/2022

Valid for credit through: 12/8/2023

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Guideline-Based Standard Management of Metastatic Triple Negative Breast Cancer

Do you know the latest guidelines for the management of metastatic triple negative breast cancer (mTNBC)?
Sara A. Hurvitz, MD

Novel Immunotherapy Strategies for Metastatic Triple Negative Breast Cancer

Are you familiar with the latest data on immunotherapy for mTNBC?
Rita Nanda, MD

New Non-IO Therapies in Triple Negative Breast Cancer: ADCs and Small Molecules

Did you know that there are multiple targeted therapies under investigation for TNBC?
Neelima Vidula, MD

Brain Metastases: Systemic and Local Therapies

Do you know the importance of multidisciplinary collaboration in the management of patients with breast cancer and brain metastases?
Carey K. Anders, MD; Priscilla Brastianos, MD

Shared Decision-Making in Palliative Care

Do you know the best communication strategies to promote shared decision-making in the palliative care setting?
Lidia Schapira, MD, FASCO
 

Educational Impact Challenge

The goal of this activity is for the learners to be better able to understand the spectrum of breast cancer treatment and provide strategies that can help translate data updates to improvements in patient care.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print